Claims for Patent: 8,475,780

Summary for Patent: 8,475,780

Title:	Ion binding polymers and uses thereof
Abstract:	The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
Inventor(s):	Charmot; Dominique (Campbell, CA), Chang; Han-Ting (Livermore, CA), Klaerner; Gerrit (Los Gatos, CA), Buysse; Jerry M. (Los Altos, CA), Liu; Mingjun (Campbell, CA)
Assignee:	Relypsa, Inc. (Redwood City, CA)
Application Number:	13/015,134
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,475,780
Patent Claims:	1. A method of treating hyperkalemia in a patient in need thereof, the method comprising administering a pharmaceutical composition to the patient, wherein the administration is oral, intestinal, or rectal, the patient being treated with a drug that may cause hyperkalemia, wherein the pharmaceutical composition comprises a crosslinked polymer having moieties comprising one or more of the following structures: ##STR00027## or an acid or salt thereof. 2. The method of claim 1 wherein the moiety is in its acid form. 3. The method of claim 1 wherein when the moiety is in its salt form and further comprises a metallic or non-metallic cationic counterion. 4. The method of claim 1 wherein the drug that may cause hyperkalemia is a potassium-sparing diuretic, an angiotensin-converting enzyme inhibitor, an angiotensin receptor blocker, a non-steroidal anti-inflammatory drug, heparin, or trimethoprim. 5. The method of claim 4 wherein the patient is being treated with an angiotensin-converting enzyme inhibitor. 6. The method of claim 4 wherein the patient is being treated with an angiotensin receptor blocker. 7. The method of claim 1 wherein the pharmaceutical composition and the drug that may cause hyperkalemia are administered simultaneously. 8. The method of claim 1 wherein the crosslinked polymer is coated with an enteric coating. 9. The method of claim 1 wherein the pharmaceutical composition is administered in a dose to deliver from about 0.5 g to about 30 grams per day of the crosslinked polymer. 10. The method of claim 1 wherein the pharmaceutical composition is administered in a dose to deliver from about 5 g to about 25 grams per day of the crosslinked polymer. 11. The method of claim 1 wherein the pharmaceutical composition is administered chronically to said patient. 12. A method of treating a patient, the method comprising administering to the patient a drug that may cause hyperkalemia and a pharmaceutical composition, wherein the pharmaceutical composition comprises a crosslinked polymer having moieties comprising one or more of the following structures: ##STR00028## or an acid or salt thereof. 13. The method of claim 12 wherein the moiety is in its acid form. 14. The method of claim 12 wherein when the moiety is in its salt form and further comprises a metallic or non-metallic cationic counterion. 15. The method of claim 12 wherein the drug that may cause hyperkalemia is a potassium-sparing diuretic, an angiotensin-converting enzyme inhibitor, an angiotensin receptor blocker, a non-steroidal anti-inflammatory drug, heparin, or trimethoprim. 16. The method of claim 15 wherein the patient is being treated with an angiotensin-converting enzyme inhibitor. 17. The method of claim 15 wherein the patient is being treated with an angiotensin receptor blocker. 18. The method of claim 12 wherein the pharmaceutical composition and the drug that may cause hyperkalemia are administered simultaneously.